| β-blockers | ACEIs | ARBs | CCBs | Diuretics | α1 adrenergic blockers |
---|---|---|---|---|---|---|
Whole population (n = 129) | 45 (34.9) | 39 (30.2) | 55 (42.9) | 25 (19.4) | 60 (46.9) | 7 (5.4) |
 Class I (n = 59) | 13 (22.0) | 25 (42.3) | 23 (38.9) | 16 (27.1) | 26 (44.1) | 1 (1.7) |
 Class II (n = 34) | 19 (55.9) | 6 (17.6) | 16 (47.1) | 5 (14.7) | 18 (52.9) | 1 (2.9) |
 Class III (n = 36) | 13 (36.1) | 8 (22.0) | 16 (44.4) | 4 (11.1) | 16 (47.1) | 5 (13.9) |
Only antihypertensive (n = 104) | 35 (33.7) | 33 (31.7) | 45 (43.3) | 20 (18.3) | 48 (46.2) | 4 (3.7) |
 Class I (n = 46) | 10 (21.7) | 18 (39.1) | 20 (43.5) | 12 (26.1) | 21 (45.7) | 1 (2.2) |
 Class II (n = 29) | 14 (48.3) | 6 (20.7) | 13 (44.8) | 4 (13.8) | 15 (51.7) | 1 (3.4) |
 Class III (n = 29) | 11 (37.9) | 9 (31.0) | 12 (41.4) | 4 (13.8) | 12 (41.4) | 2 (6.8) |